Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome.
about
Nonalcoholic fatty liver disease: a comprehensive review of a growing epidemicPleiotropic effects of statins in the diseases of the liverGenetics of non-alcoholic fatty liver disease: From susceptibility and nutrient interactions to managementInsulin resistance in development and progression of nonalcoholic fatty liver diseaseMicroRNAs in Nonalcoholic Fatty Liver DiseaseNew obesity classification criteria as a tool for bariatric surgery indicationIncretin based therapies: a novel treatment approach for non-alcoholic fatty liver diseaseThe adipokine/ceramide axis: key aspects of insulin sensitizationChronic alcohol consumption potentiates the development of diabetes through pancreatic β-cell dysfunctionNIKEI: a new inexpensive and non-invasive scoring system to exclude advanced fibrosis in patients with NAFLDLipotoxic effect of p21 on free fatty acid-induced steatosis in L02 cellsThe relationship of omental and subcutaneous adipocyte size to metabolic disease in severe obesity.Acid sphingomyelinase deficiency in Western diet-fed mice protects against adipocyte hypertrophy and diet-induced liver steatosis.Fast food diet with CCl4 micro-dose induced hepatic-fibrosis--a novel animal model.Worksite health screening programs for predicting the development of Metabolic Syndrome in middle-aged employees: a five-year follow-up studyNutritional correlates and dynamics of diabetes in the Nile rat (Arvicanthis niloticus): a novel model for diet-induced type 2 diabetes and the metabolic syndrome.The Effect of Chlorella vulgaris Supplementation on Liver En-zymes, Serum Glucose and Lipid Profile in Patients with Non-Alcoholic Fatty Liver DiseaseCannabinoid receptor 1 gene polymorphisms and nonalcoholic Fatty liver disease in women with polycystic ovary syndrome and in healthy controlsEffect of dietary advanced glycation end products on mouse liverElevated alanine aminotransferase is strongly associated with incident metabolic syndrome: a meta-analysis of prospective studiesGenetic polymorphism of cytochrome P450 4F2, vitamin E level and histological response in adults and children with nonalcoholic fatty liver disease who participated in PIVENS and TONIC clinical trials.PURLs: statins for patients with nonalcoholic fatty liver?Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT studyEffects on Liver Lipid Metabolism of the Naturally Occurring Dietary Flavone Luteolin-7-glucoside.Non-Alcoholic Fatty Liver Disease Is a Risk Factor for the Development of Diabetic Nephropathy in Patients with Type 2 Diabetes MellitusRisk of de novo post-transplant type 2 diabetes in patients undergoing liver transplant for non-alcoholic steatohepatitis.Hyperinsulinemia Enhances Hepatic Expression of the Fatty Acid Transporter Cd36 and Provokes Hepatosteatosis and Hepatic Insulin Resistance.Normal liver enzymes are correlated with severity of metabolic syndrome in a large population based cohort.Overexpression of Peroxiredoxin 4 Affects Intestinal Function in a Dietary Mouse Model of Nonalcoholic Fatty Liver Disease.Long-Term Treatment with n-3 Polyunsaturated Fatty Acids as a Monotherapy in Children with Nonalcoholic Fatty Liver Disease.Menhaden oil decreases high-fat diet-induced markers of hepatic damage, steatosis, inflammation, and fibrosis in obese Ldlr-/- mice.Dose-response Relationship of Serum Uric Acid with Metabolic Syndrome and Non-alcoholic Fatty Liver Disease Incidence: A Meta-analysis of Prospective Studiesα-Tocopherol bioavailability is lower in adults with metabolic syndrome regardless of dairy fat co-ingestion: a randomized, double-blind, crossover trialPotential for dietary ω-3 fatty acids to prevent nonalcoholic fatty liver disease and reduce the risk of primary liver cancerPrevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States.Association between Insulin Resistance, Metabolic Syndrome and Nonalcoholic Fatty Liver Disease in Chinese AdultsInduction of CYP2E1 in non-alcoholic fatty liver diseases.Focus on therapeutic strategies of nonalcoholic Fatty liver diseaseImpact of dietary fat on the development of non-alcoholic fatty liver disease in Ldlr-/- mice.Nordihydroguaiaretic acid improves metabolic dysregulation and aberrant hepatic lipid metabolism in mice by both PPARα-dependent and -independent pathways.
P2860
Q24563381-E6440957-AB91-42B9-B098-73333EA60788Q26741176-C435526A-43F2-444E-A7E6-9FD4F8445807Q26741557-8D174AD8-60E2-4964-81B1-E20C56482BC6Q26748687-97FD0394-3680-4A67-B0DD-48820CCE00CBQ26774294-F12BD504-1BB4-44C5-898A-4312411502F0Q26774656-826C7B44-D2E9-4FF0-895B-CC285CDCCD48Q26827183-20BD7CD2-4315-4C6A-AAC3-6F768E8EB6AFQ27025041-0463A841-25E4-45C6-A9C5-3350BBE84605Q28082228-003DFF90-14E3-45BF-BCA2-2F774FE66A87Q28488938-7B3E094F-8C99-4B0E-BB23-7C72EBDBF38BQ28538284-2183C880-B5BF-4286-9CDF-3731647CC6DFQ33550783-3A46FF2F-8493-4FB1-8283-CE6F9A8F6A88Q33600495-8742AEFE-262F-4D18-A582-A9C2D8F0F62EQ33675416-A5EEF3D6-0B56-4D6D-8A18-56195121C897Q33761805-5CE53FC7-0151-457E-8DB6-309D16109C0BQ33843310-4B1BF7F3-971E-4C2A-BF2E-3C2ADE6C115DQ34003370-C1AF1C98-221B-4D67-8F9E-2E748520E249Q34022349-036CBB61-7B89-4F69-B9DB-A4C5BBFA23DAQ34230496-3C165CF3-063A-460A-96B7-DF306A41F06BQ35063759-C5F80409-E5F2-42DD-9B77-6890B54CC39AQ35156042-2956A706-64D0-4EEA-9D60-B5C81A3285CCQ35247558-8ABDC2C4-3706-4139-8605-1D394FE47DADQ35674320-08450920-8AC0-42C0-B96C-074B1C6D52E4Q35737798-27CAAC50-FEF2-4D65-99E4-7E0D47E8A91FQ35841020-A9F4474B-D272-4ECD-9D0C-45271F3938AEQ35868386-698A4432-5A37-4C86-8BBB-CF7CF917EA89Q35905331-2B838D68-8B94-41E2-BC4E-868C458CD900Q35948791-7030A049-446C-4CFF-A078-126C66106216Q35976733-0A0BB874-F75C-4C11-BEEA-934447F87BDCQ36038820-00F06E60-470C-4238-9A73-2152C348DABAQ36096333-BA71B666-4E3C-43B4-A369-CDF6406AEFAEQ36099467-34009FC0-5F11-4283-8A66-2178F1FAD464Q36223074-F6186BDA-0CA9-4383-91EC-E96A75B1125FQ36273224-9689DE46-A9BE-494F-BAFB-277541088E65Q36324068-C6FB0C1F-49BB-40E8-939E-EB5B3670D320Q36348736-3AE433D5-6088-4CBC-BFEB-DE271DFBE09EQ36372912-F4D00B81-020F-4FC2-BA9C-095B1654E37CQ36413703-5A1ABBFB-1205-4CB7-8B49-1CD13C624832Q36483906-2FF13181-35E7-41DE-A963-27FF506D7CA3Q36527942-A8CA8D33-9B97-4CDD-9014-E8AD5D025253
P2860
Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome.
description
2008 nî lūn-bûn
@nan
2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome.
@ast
Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome.
@en
Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome.
@nl
type
label
Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome.
@ast
Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome.
@en
Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome.
@nl
prefLabel
Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome.
@ast
Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome.
@en
Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome.
@nl
P356
P1476
Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome
@en
P2093
Chin Hee Kim
Zobair M Younossi
P304
P356
10.3949/CCJM.75.10.721
P577
2008-10-01T00:00:00Z